Journal of Advances in Medicine and Medical Research

Nanoscale modification of titanium (Ti) implant surfaces is widely presented as the natural successor to the moderately rough microtextures that underpin contemporary clinical success. This critical narrative review evaluates whether the accumulated evidence supports that claim, moving beyond a catalogue of surface technologies to interrogate the strength, consistency and translational maturity of the underlying literature. Peer-reviewed studies, authoritative reviews and institutional evidence were selected through structured searching of openly accessible scholarly indexes and appraised for methodological quality, evidence-claim alignment and internal consistency. The synthesis is organised around biological mechanisms, fabrication-related confounding, the unresolved question of optimal feature dimensions, the transition from cell culture to living tissue, and the competing design objectives introduced by antibacterial and immunomodulatory functionalisation. The available evidence indicates that nanoscale features engage integrin-mediated adhesion and can accelerate early osteoblast responses and peri-implant bone formation. Confidence in a single defined optimum is nonetheless undermined by a genuine and unreconciled disagreement over the most favourable titania nanotube diameter, by the near-inseparability of nanotopography from co-varying changes in surface chemistry, oxide crystallinity and wettability, and by a pronounced dependence of outcomes on cell type and maturation state. Early gains in stability and bone-to-implant contact observed in animal models and short clinical series tend to attenuate as healing progresses, and no consistent long-term advantage over modern microrough controls has been demonstrated. Antibacterial and osteoimmunomodulatory strategies add functional value but introduce trade-offs, because the feature dimensions that favour osteogenesis do not necessarily coincide with those that maximise bactericidal or pro-healing immune responses. The field remains dominated by short-term in vitro endpoints, heterogeneous characterisation and small clinical samples concentrated in a limited number of laboratories. Nanoscale engineering is therefore best regarded as a promising but incompletely validated refinement rather than an established clinical improvement, and priority should shift towards decoupled mechanistic studies, standardised reporting and adequately powered long-term trials.